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Abstract
Purpose To assess the effects of a new ejaculation-sparing thulium laser enucleation of the prostate (ES-ThuLEP) technique 
on sexual functions and micturition, in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia 
(BPH) and to evaluate how the surgical technique of ES-ThuLEP can lead to ejaculation preservation.
Methods A prospective study was carried out between January 2015 and January 2018 on patients with surgical indication 
for BPH, who wished to preserve ejaculation. The patients were treated with ES-ThuLEP and were evaluated before and 3 
and 6 months after surgery. Three validated questionnaires (ICIQ-MLUTSsex, IIEF-5 and IPSS) were used to assess changes 
in ejaculation, erectile function and urinary symptoms. Uroflowmetry (Qmax and Qavg), post-void residual volume and 
voided volume were also evaluated, to assess micturition improvement. Patients with moderate to severe erectile dysfunction 
were excluded. Statistical analysis was performed with the Student’s t test, Chi-square test and logistic regression analysis.
Results Two hundred and eighty three patients were enrolled. Ejaculation was spared in 203 and 219 patients at 3 and 
6 months after surgery. No significant differences were observed between erectile function before and after surgery: baseline 
IIEF-5 = 16.2 ± 4.47 vs 16.7 ± 2.9 (p = 0.419) and 17.7 ± 3.2 (p = 0.410) at 3 and 6 months. Significant improvement in urinary 
symptoms was achieved: baseline IPSS = 19.4 ± 7.24 vs 5.8 ± 4.3 (p = 0.032) and 3.9 ± 4.1 (p = 0.029) at 3 and 6 months.
Conclusion ES-ThuLEP effectively preserved ejaculation in over two thirds of the patients without compromising micturition 
improvement or erectile function. ES-ThuLEP could be a valid treatment option for BPH in young and sexually active men.
Keywords Ejaculation · Ejaculatory dysfunction · Ejaculation sparing · Benign prostatic hyperplasia · Lower urinary tract 
symptoms · Thulium laser · ThuLEP · Endoscopic enucleation of the prostate
Introduction
Benign prostatic hyperplasia (BPH) is a common condition 
in aging men, which leads to lower urinary tract symptoms 
(LUTS) and sexual dysfunction, negatively impacting on 
the patients’ quality of life [1, 2]. Despite allowing relief 
from LUTS, classical medical and surgical treatments for 
BPH have always been burdened by important consequences 
on the patients’ ejaculatory function. Over the past three 
decades research has focused on the developement of new 
surgical strategies to reduce morbidity and complications 
of conventional surgical procedures, such as transurethral 
resection of the prostate (TURP) and open prostatectomy 
(OP), but in most cases overlooking the impact on the 
patients’ ejaculatory function. Thanks to the advent of laser 
technologies, endoscopic enucleation of the prostate (EEP) 
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techniques have been developed [3, 4]. These mimick an 
OP, which is achieved endoscopically, using a laser, or a 
bipolar resector to enucleate the adenoma, imitating the use 
of the finger during OP, but maintining minimal invasive-
ness of TURP. Holmium laser enucleation of the prostate 
(HoLEP) [5] and thulium laser enucleation of the prostate 
(ThuLEP) [6] are the most demanded laser EEP techniques 
(LEEP). Both determine excellent resolution of LUTS and 
improvement in voiding parameters, comparable to those of 
TURP and OP, but with reduced morbidity, catheterization 
time and hospital stay. Moreover, they allow to treat pros-
tates of virtually all sizes [7–10]. Reasons for which, EAU 
Guidelines reccomend to resort to OP only in the abscence 
of an EEP system [11]. Despite the well documented advan-
tages of LEEP techniques over TURP and OP, they have not 
been able to overcome postoperative ejaculatory dysfunction 
(EjD) [12, 13].
The only reccomended ejaculation-sparing (ES) proce-
dure today [11], is the prostatic urethral lift, which consists 
in the positioning of suture-based implants under cysto-
scopic guidance, to compress the lateral lobes [14]. Despite 
being a valid treatment option, especially in elderly and frail 
patients [15] and despite excellent outcomes on ejaculation, 
it does not achieve the same micturition improvement of 
TURP [16]. Moreover, it is only reccomended for small 
prostates (< 70 cc) and it does not remove the hyperplastic 
tissue. Other novel, minimally invasive, non-ablative surgi-
cal techniques such as Aquablation, Rezum, and prostatic 
artery embolization, despite presenting more favourable out-
comes on ejaculation compared to TURP, are still considered 
“under investigation” by EAU Guidelines, due to the lack of 
randomized controlled trials, with a long-term follow-up, 
investigating their safety and efficacy [11, 17].
Before the ‘90 s ejaculation was thought to be a 4-phase 
process [18], which consisted of:
1. Erection.
2. Emission of semen into the prostatic urethra, closed 
between the internal sphincter (bladder neck) and the 
external sphincter.
3. Formation of a pressure chamber inside the prostatic 
urethra.
4. Expulsion of semen through the external sphincter.
According to this theory, loss of ejaculation after endo-
scopic surgery was and is still attributed by many to the 
removal of the internal sphincter, causing retrograde ejacu-
lation [19].
However, evidence on ejaculation physiology has dem-
onstrated the importance of the tissues surrounding the veru 
montanum, rather than the bladder neck, for outward ejacu-
lation [20]. Dynamic transrectal ultrasonography (TRUS) 
has shown how, just before ejaculation, the veru montanum 
undergoes a caudal shift, making contact with the anterior 
wall of the urethra, allowing the antegrade progression of 
semen, which is emitted into the inframontanal urethra 
and expelled, almost simoultaneously, through the external 
sphincter [21]. No accumulation of semen inside the pros-
tatic urethra, and therefore, generation of a high pressure 
area was demonstrated. A fundamental role in this process is 
played by the musculus ejaculatorious, a longitudinal strain 
of muscle fibres, which originate from around the ejacula-
tory ducts and extend caudally in the urethral crest, inserting 
below the urethral sphincter. Contraction of the musculus 
ejaculatorious could be responsible not only for the emis-
sion of semen from the ejaculatory ducts into the prostatic 
urethra, but also for the correct movement of the veru mon-
tanum during ejaculation [21, 22].
Based on these findings, supramontanal and paracollicu-
lar tissue-sparing surgical techniques have been developed. 
ES techniques have been applied to TURP and photoselec-
tive vaporization of the prostate (PVP) with encouraging 
results [23–25]. However, TURP and PVP are currently rec-
comended only for the treatment of small to intermediate 
size prostates [11]. Considering that LEEP techniques have 
already proved to be size indipendent [9, 10], we decided to 
modify classical ThuLEP surgery, by sparing 1.5 cm of tis-
sue above the veru montanum and two hills of tissue at the 
apex of the lateral lobes, to evaluate whether such approach 




A prospective study was carried out between January 2015 
and January 2018 on patients suffering from LUTS sec-
ondary to BPH, with surgical indication according to EAU 
Guidelines [11], who wished to preserve ejaculation. All 
the patients who met the inclusion criteria were enrolled 
and treated with ES-ThuLEP. Patients > 75 years of age, or 
with moderate to severe erectile dysfunction (IIEF-5 < 12), 
or who had undergone previous abdominal surgery, or open/
endoscopic surgery for BPH were excluded. Patients were 
assessed with a physical and digital transrectal examination, 
prostate specific antigen (PSA) levels, TRUS, suprapubic 
ultrasonography, to assess post-void residual volume (PVR), 
urine culture and uroflowmetry, to assess flow peak (Qmax) 
and average flow (Qavg).
To assess changes in ejaculation, erection and urinary 
symptoms 3 validated questionnaires were used: the ICIQ-
MLUTSsex, the IIEF-5 and the IPSS. Patients were evalu-
ated preoperatively and 3 and 6 months postoperatively. 
Patients under alfa-blocker therapy were asked to suspend 
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treatment 1 month before surgery, to assess the presence of 
preoperative ejaculation. PVR, Qmax and Qavg were also 
evaluated during follow-up.
The study was approved by our local Ethical Committee 
(approval n° ASLMI2/201400327) and all patients signed 
the informed consent.
Surgical technique
The surgical technique is a modification of the original 
ThuLEP described by Herrmann et al. [6]. Instead of per-
forming the initial inverted-U incision surrounding the veru 
montanum, the incision is shifted 1.5 cm cranial to the veru 
montanum. The incision is then extended towards the lateral 
lobes, leaving a small hill of prostatic tissue at the apex of 
the lateral lobes, each side of the veru montanum. After this 
tissue-sparing approach, the surgical procedure is performed 
as described by Herrmann, enucleating the median and lat-
eral lobes separately.
The Piranha Morcellator (Richard Wolf) was used at the 
end of the enucleation to remove the enucleated prostatic 
lobes.
All ES-ThuLEP procedures were performed by one sur-
geon (GB), with a previous experience of more than 1000 
conventional ThuLEPs, using the 200 W-Cyber-TM laser 
generator (Quanta System). A maximum power of 120 W 
was set for cutting and 35 W for coagulation.
Statistical analysis
Statistical analysis was carried out to assess patients’ data 
and outcomes (Student’s t test, Chi-square test, and logistic 
regression analysis). All reported p values were obtained 
with the two-sided exact method at the conventional 5% 
significance level. Data were analyzed using the R software 
v.3.2.3 (by The R Foundation for Statistical Computing, 
Vienna, Austria), according to previously published guide-
lines for the reporting of statistics [26].
Results
Two hundred and eighty three patients were finally enrolled. 
Patients’ preoperative characteristics are listed in Table 1. 
Intra and perioperative findings, complications and inciden-
tal findings are shown in Table 2. Follow-up parameters are 
shown in Table 3: significant improvement in IPSS, Qmax, 
Qavg and PVR were obtained at 3 and 6 months; no sig-
nificant differences were observed between erectile function 
before and after surgery according to the IIEF-5; analysis of 
postoperative ICIQ-mLUTSsex showed 203 patients (71.7%) 
with persistant ejaculation at 3 months and 219 patients 
(77.4%) at 6 months from the procedure. No significant 
differences were observed between ejaculation and erection 
preservation in patients with different prostate volumes.
Discussion
Loss of ejaculation, due to either retrograde or dry ejacu-
lation, has always been considered as the price to pay to 
achieve relief from LUTS and QoL improvement, both with 
medical treatment (alfa-blockers) and after surgery [12]. In 
recent years LEEP techniques have proved to be excellent 
alternatives to TURP and OP in terms of LUTS resolution, 
allowing to reduce morbidity and complications [7–10]. 
However, despite excellent functional outcomes, these pro-
cedures have not been able to avoid postoperative EjD [12, 
13]. Data have shown that the impact on sexual functions is 
comparable between HoLEP and TURP and that ejaculation 
and orgasm perception are the two most impacted domains 
after these procedures [27]. Similarly to HoLEP, ThuLEP 
causes retrograde ejaculation, despite having a silghtly infe-
rior relative risk compared to standard TURP [28, 29].
Reduced sexual satisfaction, due to the loss of ejacula-
tion, could discourage men from undergoing surgery for 
BPH, delaying treatment, causing worstening of symptoms 
and damage to the bladder detrusor muscle. Therefore, 
an ES approach would be the ideal option, especially for 
young and sexually active men. Based on evidence regard-
ing ejaculation physiology, which has highlighted the key 
role of the supramontanal and pericollicular tissue and 
of the musculus ejaculatorius [20–22], modifications to 
classical endoscopic surgical techniques have been cre-
ated to preserve these areas of tissue and ejaculation. In 
1998 Ronzoni et al. presented a pilot ejaculation-preserv-
ing TURP on 45 patients with small prostates, by sparing 
more than 1 cm of prostatic urethra above the veru mon-
tanum. 80% of the patients maintained their ejaculation. 
To note, the bladder neck tissue, which in the past was 
thought to be fundamental for the ejaculatory function, 
Table 1  Preoperative characteristics
Age (years): mean ± SD (range) 64.21 ± 9.74 (52–75)
Prostate volume (cc): mean ± SD (range) 82.13 ± 64.44 (21–235)
Adenoma volume (cc): mean ± SD (range) 67.84 ± 61.99 (6–215)
PSA (ng/ml): mean ± SD (range) 3.6 ± 3.1 (0.5–13.8)
Qmax (ml/s): mean ± SD (range) 9.5 ± 5.7 (3.5–13.2)
Qavg (ml/s): mean ± SD (range) 4.8 ± 2.3 (2.5–8.1)
Voided volume (ml): mean ± SD (range) 184 ± 101 (79–302)
PVR (ml): mean ± SD (range) 262 ± 145 (120–402)
Previous α-blocker therapy: n (%) 221 (78.1%)
Previous α-blocker + 5α-reducatase inhibitor 
therapy: n (%)
35 (12.4%)
Previous TRUS biopsy: n (%) 71 (25.1%)
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was entirely removed [23]. Alloussi et al. presented their 
modified ejaculation-preserving TURP (EP-TURP) on 86 
patients, with a 60-month follow-up, which not only spared 
the supramontanal tissue, but also the paracollicular tis-
sue. Significant IPSS, PVR and Qmax improvement were 
achieved, comparable to standard TURP and ejaculation 
was preserved in 90.8% of the patients [24]. Talab et al., 
instead, presented a video-article showing their EP-PVP: 
similarly to Alloussi et al. the supramontanal and paracol-
licular tissues were preserved; 160 patients were analyzed, 
with a maximum follow-up of 74 months; results seemed 
promising: significant improvement in voiding parameters 
was achieved and ejaculation was maintained in 86.6% of 
the patients [25].
Despite the different energy sources employed (elec-
trocautery vs laser), preservation of the paracollicular and 
supramontanal tissues has proved to significantly increase 
ejaculation preservation, confirming the importance of the 
anatomical structures that have been described in these 
areas. Considering these encouraging results we modified 
classical ThuLEP as described above. We performed a pro-
spective study on 283 patients, who underwent ES-ThuLEP, 
to investigate the impact of this technique on ejaculation, 
erection and micturition. Our series showed an overall con-
servation of antegrade ejaculation in 71.7% of the patients 
at 3 months, which improved to 77.4% at 6 months. We also 
performed a post hoc evaluation of ejaculation preservation 
in patients with different prostatic volumes (< 40 cc, ≥ 40 
and ≤ 100 cc and > 100 cc), to evaluate whether large pros-
tates could compromise the outcome of the procedure. No 
significant differences were found (Table 3), confirming that 
ES-ThuLEP allowed to effectively maintain ejaculation no 
matter what prostate size.
To the best of our knowledge, only one ES-LEEP tech-
nique has been presented before, by Kim et al. the Ejacu-
latory-hood HoLEP (EH-HoLEP) [30]. In their study 26 
patients who underwent EH-HoLEP were compared to 
other 26 patients who underwent standard HoLEP. Ejacu-
lation was maintained in 46.2% of the patients who under-
went EH-HoLEP vs 26.9% of the patients who underwent 
conventional HoLEP. However, this difference was not 
statistically significant. The small number of patients 
analized by Kim et al. the difference in technique between 
EH-HoLEP and ES-ThuLEP and the different features 
between the holmium and thulium lasers could explain 
the better outcomes achieved with ES-ThuLEP and the 
other ES procedures. Similarly to other ES techniques, 
Kim et al. preserved 1 cm of tissue above the veru mon-
tanum, but only 2–3 mm of tissue around each side of it, 
with a radical enucleation of the prostatic apex. Whereas, 
with ES-ThuLEP two entire hills of tissue are preserved 
at the prostatic apex, each side of the veru montanum, 
together with 1.5 cm of tissue above the veru montanum. 
The importance of this wider tissue preservation is dem-
onstrated in the video by Talab et al. [25], which shows 
the proximity of the ejaculatory ducts to the apical pro-
static tissue. Sparing of this wider area of tissue at the 
prostatic apex, allows to better preserve the ejaculatory 
ducts and the muscular fibres surrounding them, which 
have an important role in the emission of semen and in 
Table 2  Intra and perioperative parameters, complications and incidental findings
Intra and perioperative parameters
 Operative time (minutes): mean ± SD 81 ± 62
 Enucleated tissue weight (g): mean ± SD 90.7 ± 45.3
 Stop bladder irrigation (hours): mean ± SD 24.2 ± 16.8
 Catheter removal (hours): mean ± SD 51 ± 16.9
 Hospitalization (days): mean ± SD 3.6 ± 2.8
 Haemoglobin drop (g/dl): mean ± SD 2.89 ± 1.72
 Transfusions: n (%) 4 (1.4%)
Complications and incidental findings
 Acute urinary retention: n (%) 6 (2.1%)
 Re-intervention for bleeding: n (%) 3 (1.1%)
 Transitory postoperative incontinence: n (%) 1 (0.4%)
 Bladder neck sclerosis: n (%) 1 (0.4%)
 Pain/discomfort during ejaculation at 3 months: n (%) 15 (5.3%)
 Pain/discomfort during ejaculation at 6 months: n (%) 7 (2.5%)
 Haemospermia at 3 months: n (%) 151 (53.3%)
 Haemospermia at 6 months: n (%) 79 (27.9%)
 Incidental prostate adenocarcinoma: n (%) 12 (4.2%)
 Incidental presence of bladder cancer: n (%) 3 (1.1%)
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the conformational changes of the prostatic urethra dur-
ing ejaculation [20–22]. The shallower penetration of the 
thulium laser compared to the holmium laser (0.25 vs 
0.4 mm) [31] and its continous wave output also allow to 
reduce the damage on these important structures and opti-
mize their preservation. Whereas, the holmium laser, with 
its pulsed output, ruptures the tissue and more traction 
with the tip of the resectoscope is needed to separate the 
adenoma from the capsule, increasing mechanical stress 
on the surrounding tissues.
Differences in ejaculation-preserving rates could also 
be due to different surgical experiences and surgical vol-
ume. In this study the surgeon (GB) had previously per-
formed more than 1000 classical ThuLEPs, which makes 
the surgeon very familiar with the equipment, the tech-
nique and the surgical landmarks. However, the other cited 
studies did not report previous surgical experience.
With regard to micturition improvement, we regis-
tered a mean IPSS of 5.8 ± 4.3 (p = 0.032) at 3 months 
and 3.9 ± 4.1 (p = 0.029) at 6 months. Qmax improved to 
23.2 ± 7.2 ml/s (p = 0.021) and 24.1 ± 5.6 ml/s (p = 0.026) 
at 3 and 6 months, respectively (Table 3). This improve-
ment is comparable to that registered in a previous study 
after standard ThuLEP, involving the same surgeon [28]. 
It is common thought amongst urologists, that leaving tis-
sue at the prostatic apex means not disobstructing patients 
completely. The improvement in postoperative IPSS, 
flowmetry parameters and PSA that were registered in our 
study (Table 3), contradict this way of thinking and indi-
cate that ES-ThuLEP allows to achieve significant micturi-
tion and LUTS improvement. This could be related to the 
fact that, most of the obstruction in BPH, is secondary 
to the contraction of the prostatic smooth muscle fibres 
and to the pressure of the growing hyperplastic tissue on 
the prostatic capsule, which is directly transmitted to the 
prostatic urethra.
No changes in erectile function were observed during fol-
low-up according to the IIEF-5 (Table 3), similarly to previ-
ously reported results for classical ThuLEP [28]. ES-ThuLEP 
also proved to be safe, with only 3 cases of postoperative 
haematuria requiring re-intervention, 6 cases of acute urinary 
retention (treated with bladder catheterization for 10 days and 
steroid oral therapy), 1 case of bladder neck sclerosis (treated 
with laser vaporization of the bladder neck) and 1 case of post-
operative transitory incontinence, which was resolved at the 
3-month follow-up (Table 2). At the 3-month follow-up 15 
patients (5.3%) reported occasional pain/discomfort during 
ejaculation, which reduced to 7 (2.5%) at the 6-month follow-
up; 151 patients (53.3%) reported occasional haemospermia at 
the 3-month follow-up and 79 patients (27.9%) at the 6-month 
follow-up. These findings are not uncommon in patients after 
BPH surgery. However, most studies do not report these 
individual outcomes, generally speaking of postoperative 
ejaculatory dysfunction, making it difficult to compare these 
findings.
The main limits of this study are the absence of a control 
group and its short follow-up. However, the primary outcome 
of the study was to assess the efficacy of this modified tech-
nique in preserving patients’ ejaculation; therefore, a long 
follow-up was not planned. Future controlled trials will allow 
to better determine the ejaculation-preserving rate of this tech-
nique compared to standard ThuLEP. A longer follow-up, also 
evaluating re-intervention rate, will allow to understand if re-
growth of the preserved apical tissue could be responsible for 
deterioration in micturition and LUTS. Nevertheless, consid-
ering the large amount of patients involved, our results seem 
promising, allowing to give patients, who wish to maintain 
ejaculation, a chance.
Conclusions
ES-ThuLEP allows to effectively preserve ejaculation in more 
than two thirds of the patients, no matter what prostate size, 
without compromising micturition improvement or erectile 
function and maintaining a low complication rate, making it a 
valid treatment alternative for young and sexually active men 
suffering from BPH.
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